CV Therapeutics Earnings Conference Call (Q4 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 20 Calls Today's Calls

Call Details CV Therapeutics Earnings Conference Call (Q4 2008) Fri, Feb 20, 2009, 8:30 am Eastern Listen to the archived event audio About CV Therapeutics (NasdaqGM:CVTX) CV Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. It develops advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The company’s approved product Ranexa (ranolazine extended-release tablets) is used for the treatment of chronic angina. Its product candidates under clinical development include Ranexa for the reduction of hemoglobin A1c and arrhythmias in coronary artery disease patients with diabetes; Regadenoson for use as a pharmacologic stress agent in myocardial perfusion imaging studies; Tecadenoson, a selective A1-adenosine receptor agonist for the reduction of rapid heart rate during acute atrial arrhythmias, which is in Phase III clinical development stage; Adentri, a Phase II clinical trial product for the treatment of heart failure; and CVT-6883, a Phase I clinical trial product for the treatment of cardiopulmonary disease. The company also has various preclinical development programs, including CVT-3619 for the treatment of diabetes/metabolic syndrome; CVT-10,216 for alcohol addiction; Late I to treat coronary artery disease; SC Desaturase used for treating obesity/metabolic syndrome; A2A antagonist for chemical dependence; ABCA1/ApoA-I for the treatment of atherosclerosis; and Drug-Eluting Stent Program for the treatment of restenosis. CV Therapeutics has strategic alliances with Astellas Pharma, Inc.; Biogen Idec, Inc.; PTC Therapeutics, Inc.; and Roche Palo Alto LLC. The company was founded in 1990 and is headquartered in Palo Alto, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings